Amneal Eyes Avastin And Praises $120m Biosimilar Development Savings
‘We Are Here To Stay’ US Firm Says Of Biosimilar Ambitions
Amneal is close to a filed pipeline of three biosimilar products in the US, while furthering ambitions in the complex generics and 505(b)(2) space, management told the virtual J.P. Morgan Healthcare Conference.
You may also be interested in...
Teva has launched its generic version of NuvaRing in the US, adding a second rival generic to the market that already includes Amneal, as well as an authorized generic version from Prasco.
Amneal will take a majority stake in Kashiv Specialty Pharmaceuticals after striking a deal worth potentially more than $100m for a 98% stake in the hybrid 505(b)(2) and complex generics specialist.
After launching several high-value complex generic products in the last six months, Amneal aims to launch eight more complex generics by August 2021 to add “tremendous value” to its generics business.